Item 8.01. Other Information
On January 21, 2021, Surface Ophthalmics, Inc. ("Surface") issued a press
release (the "Surface PR") reporting positive top-line results from a Phase II
trial of its drug candidate SURF-201, a 0.2% betamethasone, preservative-free
ophthalmic solution in the Klarity® delivery vehicle for the treatment of post
cataract surgery pain and inflammation. According to the Surface PR, SURF-201
was dosed twice daily, and met its primary endpoints of absence of inflammation
at both Day 8 and Day 15 and was found to be safe and well-tolerated by the
patient group. In addition, a secondary endpoint showed almost 90% of patients
given SURF-201 were pain free at Day 15. SURF-201 marks the first ophthalmic
therapeutic in the United States to utilize betamethasone as well as being the
first preservative-free unit dose therapy for the treatment of post-operative
pain and inflammation.
Harrow Health, Inc. currently owns three million five hundred thousand
(3,500,000) shares of Surface common stock, which is approximately 30% of the
issued and outstanding voting interests of Surface, along with a mid-single
digit royalty right on net sales of SURF-201.
The foregoing is only a brief description of the Surface PR, does not purport to
be a complete description of the Surface PR and is qualified in its entirety by
reference to the full text of the document, which is filed as Exhibit 99.1 to
this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Item Description
99.1 Surface Ophthalmics Press Release Date January 21, 2021
© Edgar Online, source Glimpses